Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

NCT07287917 is registered in ClinicalTrials.gov with Aminex Therapeutics, Inc. as lead sponsor.

NCT NCT07287917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies
Lead sponsor
Aminex Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 26, 2026
Completion date
December 29, 2028
Enrollment
92 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

her2-low hormone receptor positive breast cancer, melanoma (skin cancer)